For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
31
views
4
references
 Top references
cited by
350
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      483
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: not found

      Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of sacubitril-valsartan therapy is safe and effective among patients who are hospitalized for acute decompensated heart failure is unknown.

          Related collections

          Most cited references4

          • Record: found
          • Abstract: found
          • Article: not found

          The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.

          Andrew Ambrosy, Gregg C. Fonarow, Javed Butler … (2014)
          Heart failure is a global pandemic affecting an estimated 26 million people worldwide and resulting in more than 1 million hospitalizations annually in both the United States and Europe. Although the outcomes for ambulatory HF patients with a reduced ejection fraction (EF) have improved with the discovery of multiple evidence-based drug and device therapies, hospitalized heart failure (HHF) patients continue to experience unacceptably high post-discharge mortality and readmission rates that have not changed in the last 2 decades. In addition, the proportion of HHF patients classified as having a preserved EF continues to grow and may overtake HF with a reduced EF in the near future. However, the prognosis for HF with a preserved EF is similar and there are currently no available disease-modifying therapies. HHF registries have significantly improved our understanding of this clinical entity and remain an important source of data shaping both public policy and research efforts. The authors review global HHF registries to describe the patient characteristics, management, outcomes and their predictors, quality improvement initiatives, regional differences, and limitations of the available data. Moreover, based on the lessons learned, they also propose a roadmap for the design and conduct of future HHF registries. Copyright © 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
          Article 0 comments Cited 705 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found
            Is Open Access

            Rationale and design of the com P ar I son O f sacubitril/valsarta N versus E nalapril on E ffect on nt-p R o-bnp in patients stabilized from an acute H eart F ailure episode (PIONEER-HF) trial

            Adrian Hernandez, Eugene Braunwald, Carol I. Duffy … (2018)
            The objective is to assess the safety, tolerability, and efficacy of sacubitril/valsartan compared with enalapril in patients with heart failure (HF) with a reduced ejection fraction (EF) stabilized during hospitalization for acute decompensated HF.
            Article 0 comments Cited 18 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions

              Andrew Ambrosy, Robert J Mentz, Mona Fiuzat … (2018)
              Article 0 comments Cited 13 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (iso-abbrev): N. Engl. J. Med.
                Title: The New England journal of medicine
                Publisher: Massachusetts Medical Society
                ISSN (Electronic): 1533-4406
                ISSN (Print): 0028-4793
                Publication date (Electronic): February 07 2019
                Volume: 380
                Issue: 6
                Affiliations
                [1 ] From the Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (E.J.V.); the Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston (D.A.M., E.B.); Duke Clinical Research Institute, Duke University, Durham, NC (A.D.D.); Novartis Pharmaceuticals, East Hanover, NJ (C.I.D., K.M., R.R.); and the Division of Cardiology, Permanente Medical Group, San Francisco, and the Division of Research, Kaiser Permanente Northern California, Oakland - both in California (A.P.A.).
                Article
                DOI: 10.1056/NEJMoa1812851
                PubMed ID: 30415601
                SO-VID: ce5746bf-46a0-45d2-a6f8-5b6699407e19
                History

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content483

                See all similar

                Cited by400

                See all cited by

                Most referenced authors598

                See all reference authors